Tesamorelin 5mg

Tesamorelin 5mg is a peptide used to enhance muscle growth and reduce visceral fat.

Tesamorelin

What is Tesamorelin?

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to stimulate the pituitary gland to release growth hormone. It is primarily researched for its ability to reduce visceral fat in individuals with HIV-associated lipodystrophy and has potential applications in weight loss and metabolic health studies.

How It Works (Mechanism of Action)

Tesamorelin binds to GHRH receptors in the pituitary gland, triggering the release of growth hormone, which subsequently increases insulin-like growth factor-1 (IGF-1) levels. This process enhances lipolysis (fat breakdown), particularly targeting visceral adipose tissue, while also improving lipid profiles and insulin sensitivity. Unlike other GHRH analogs, Tesamorelin has a modified structure for enhanced stability and prolonged activity.

Potential Benefits & Use Cases

• Visceral Fat Reduction: Significantly reduces abdominal fat, particularly in HIV-associated lipodystrophy, with studies showing 10-18% reductions over 26 weeks.
• Weight Loss: Promotes fat loss in non-HIV populations, supporting obesity research.
• Improved Metabolic Health: Enhances lipid profiles (e.g., reduced triglycerides) and may improve insulin sensitivity.
• Cardiovascular Benefits: Potential reduction in cardiovascular risk by decreasing visceral fat and improving metabolic markers.
• Research Applications: Studied for metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and age-related fat accumulation.

Typical Dosage & Administration

Administration: Subcutaneous injection, typically administered once daily, preferably at bedtime to mimic natural growth hormone pulses.

Dosage:

• Standard Dose: 2 mg per day is the FDA-approved dose for HIV-associated lipodystrophy; research protocols may use 1-2 mg daily.
• Reconstitution: A 10mg vial is typically reconstituted with 1-2 ml bacteriostatic water, yielding 5-10 mg/ml (e.g., 2 mg = 0.2-0.4 ml). Gently swirl to mix, avoiding vigorous shaking.
• Protocol: Administered for 12-26 weeks in studies, with maintenance doses adjusted based on research goals; consult a professional for precise regimens.

Possible Side Effects

• Injection Site Reactions: Mild redness, swelling, or itching at the injection site.
• Joint or Muscle Pain: Some subjects report transient arthralgia or myalgia due to growth hormone elevation.
• Headaches: Mild headaches, typically resolving with continued use.
• Rare Glucose Intolerance: Potential for elevated blood glucose, requiring monitoring in subjects with diabetes risk.
• Water Retention: Mild edema in some cases, linked to growth hormone effects.

Side effects are generally mild and manageable with proper monitoring.

Other Relevant Details

• FDA Approval: Approved as Egrifta for HIV-associated lipodystrophy; research use extends to broader metabolic and weight loss applications.
• Storage: Lyophilized vials stored at 2-8°C; reconstituted solutions stable at 2-8°C for up to 14 days. Avoid freezing reconstituted peptide.
• Research Context: Investigated in phase 2/3 trials for NAFLD and general obesity; shows promise for reducing liver fat and improving metabolic syndrome.
• Contraindications: Not recommended for subjects with active malignancy, pituitary disorders, or pregnancy due to growth hormone stimulation.
• Not for Human Consumption: Intended for laboratory or in-vitro research only outside FDA-approved indications, per supplier guidelines.